| 纯度 | > 80 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD5 |
| Uniprot No | P06127 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-372aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSRLSWYDP DFQARLTRSN SKCQGQLEVY LKDGWHMVCS QSWGRSSKQW EDPSQASKVC QRLNCGVPLS LGPFLVTYTP QSSIICYGQL GSFSNCSHSR NDMCHSLGLT CLEPQKTTPP TTRPPPTTTP EPTAPPRLQL VAQSGGQHCA GVVEFYSGSL GGTISYEAQD KTQDLENFLC NNLQCGSFLK HLPETEAGRA QDPGEPREHQ PLPIQWKIQN SSCTSLEHCF RKIKPQKSGR VLALLCSGFQ PKVQSRLVGG SSICEGTVEV RQGAQWAALC DSSSARSSLR WEEVCREQQC GSVNSYRVLD AGDPTSRGLF CPHQKLSQCH ELWERNSYCK KVFVTCQDPN P |
| 预测分子量 | 41 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD5重组蛋白的3篇文献参考，包含作者、文献名称及摘要内容概括：
---
1. **文献名称**：*CD5 enhances the immunosuppressive function of regulatory T cells in cancer*
**作者**：Miller, J. C., & Gaulton, G. N.
**摘要**：该研究利用重组CD5蛋白，揭示了其在肿瘤微环境中增强调节性T细胞(Treg)免疫抑制功能的机制。实验表明，CD5通过与T细胞受体(TCR)相互作用，抑制效应T细胞活性，可能为癌症免疫治疗提供新靶点。
---
2. **文献名称**：*Recombinant CD5 extracellular domain inhibits T-cell activation by modulating TCR signaling*
**作者**：Lanier, L. L., & Brown, M. H.
**摘要**：作者通过表达CD5重组胞外域蛋白，证明其可阻断CD5与天然配体的结合，从而抑制T细胞活化信号通路。该研究为开发基于CD5的自身免疫性疾病治疗策略提供了理论支持。
---
3. **文献名称**：*CD5 as a therapeutic target: Structural insights from recombinant protein studies*
**作者**：Starling, G. C., & Rockson, S. G.
**摘要**：通过解析CD5重组蛋白的晶体结构，该研究阐明了其与抗体或配体结合的关键表位，并设计了靶向CD5的融合蛋白，在动物模型中验证了其缓解炎症性疾病的潜力。
---
**注**：以上文献信息为示例性内容，实际研究中请根据具体需求检索PubMed或Google Scholar获取真实文献。
CD5 is a cell surface glycoprotein belonging to the scavenger receptor cysteine-rich (SRCR) superfamily, primarily expressed on T lymphocytes and a subset of B cells (B-1 cells). It functions as a co-receptor in lymphocyte activation and immune regulation, modulating signal transduction through interactions with ligands like CD72 and CD166. CD5 plays dual roles in immunity: it dampens antigen receptor signaling to maintain self-tolerance while paradoxically enhancing inflammatory responses in specific contexts. Its involvement in autoimmune diseases and lymphoid malignancies has made it a therapeutic target of interest.
Recombinant CD5 protein refers to the engineered form produced in heterologous expression systems (e.g., mammalian cells, bacteria) for research or therapeutic applications. This protein typically retains the extracellular domain responsible for ligand binding, often fused with tags (e.g., Fc, His-tag) to facilitate purification and detection. Researchers utilize recombinant CD5 to study its immunomodulatory mechanisms, including its role in T-cell anergy, B-cell survival, and cytokine production. In therapeutic development, it serves as a tool to generate blocking antibodies for autoimmune conditions like rheumatoid arthritis or to design CD5-targeted CAR-T cells for hematologic cancers.
Structurally, recombinant CD5 preserves critical epitopes for antibody recognition and ligand interaction, enabling applications in flow cytometry, ELISA, and functional assays. Recent studies explore its potential as a decoy receptor to inhibit pathological immune responses or as a biomarker in lymphoid malignancies. Advances in protein engineering have improved its stability and bioavailability, supporting its growing utility in both basic immunology and translational medicine.
×
